» Articles » PMID: 19398572

Margin Clearance and Outcome in Resected Pancreatic Cancer

Overview
Journal J Clin Oncol
Specialty Oncology
Date 2009 Apr 29
PMID 19398572
Citations 135
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: Current adjuvant therapies for pancreatic cancer (PC) are inconsistently used and only modestly effective. Because a high proportion of patients who undergo resection for PC likely harbor occult metastatic disease, any adjuvant trials assessing therapies such as radiotherapy directed at locoregional disease are significantly underpowered. Stratification based on the probability (and volume) of residual locoregional disease could play an important role in the design of future clinical trials assessing adjuvant radiotherapy.

Patients And Methods: We assessed the relationships between margin involvement, the proximity to operative resection margins and outcome in a cohort of 365 patients who underwent operative resection for PC.

Results: Microscopic involvement of a resection margin by tumor was associated with a poor prognosis. Stratifying the minimum clearance of resection margins by 0.5-mm increments demonstrated that although median survival was no different to clear margins based on these definitions, it was not until the resection margin was clear by more than 1.5 mm that optimal long-term survival was achieved.

Conclusion: These data demonstrate that a margin clearance of more than 1.5 mm is important for long-term survival in a subgroup of patients. More aggressive therapeutic approaches that target locoregional disease such as radiotherapy may be beneficial in patients with close surgical margins. Stratification of patients for entry onto future clinical trials based on this criterion may identify those patients who benefit from adjuvant radiotherapy.

Citing Articles

Nomogram for predicting post-progression-free survival in patients with recurrent pancreatic ductal adenocarcinoma after radical surgery: a retrospective analysis.

Qin D, Xi P, Huang K, Jiang L, Yao Z, Wei R Front Med (Lausanne). 2024; 11:1486750.

PMID: 39712186 PMC: 11659012. DOI: 10.3389/fmed.2024.1486750.


Prognostic value of the CRM-status in pancreatic ductal adenocarcinoma - data from a regional cancer registry.

Schuhbaur J, Surovtsova I, Seufferlein T, Kokh D, Szotyori-Artz G, Winzler C BMC Cancer. 2024; 24(1):1280.

PMID: 39407151 PMC: 11481764. DOI: 10.1186/s12885-024-12995-z.


Intraoperative Guidance of Pancreatic Cancer Resection Using a Toll-like Receptor 2-Targeted Fluorescence Molecular Imaging Agent.

Huynh A, Cohen A, Doligalski M, Casagni T, Moberg V, Huang X Cancer Res Commun. 2024; 4(11):2877-2887.

PMID: 39320054 PMC: 11536076. DOI: 10.1158/2767-9764.CRC-24-0244.


Prognostic impact of the distance from the anterior surface to tumor cells in pancreatoduodenectomy with neoadjuvant chemoradiotherapy for pancreatic ductal adenocarcinoma.

Usui M, Uchida K, Hayasaki A, Kishiwada M, Mizuno S, Watanabe M PLoS One. 2024; 19(7):e0307876.

PMID: 39058712 PMC: 11280245. DOI: 10.1371/journal.pone.0307876.


Resection Margin Status and Long-Term Outcomes after Pancreaticoduodenectomy for Ductal Adenocarcinoma: A Tertiary Referral Center Analysis.

Quero G, De Sio D, Fiorillo C, Lucinato C, Panza E, Biffoni B Cancers (Basel). 2024; 16(13).

PMID: 39001409 PMC: 11240367. DOI: 10.3390/cancers16132347.